kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Human VEGF165, epitope tag free, ultra sensitivity (primary amine labeling), 25 µg  

Recombinant Biotinylated Human VEGF165, epitope tag free, ultra sensitivity (primary amine labeling), 25 µg

Recombinant Biotinylated Human VEGF165, Ala 27 - Arg 191, expressed from human HEK293 cells, epitope tag free, ultra sensitivity, primary amine labelin

Synonym: recombinant, human, biotinylated protein, RP1-261G23.1, MGC70609, MVCD1, VEGFA, VPF, VEGF165, biotin-VEGF, btn-VEGF

More details


325,00 €

is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.

Recombinant Biotinylated Human VEGF165, epitope tag free, primary amine labeling(VE5-H8210) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 191 (Accession # P15692-4).
Predicted N-terminus: Ala 27

Molecular Characterization
This protein carries no "tag".
The protein has a calculated MW of 19.2 kDa. The protein migrates as 23-25 kDa under reducing (R) condition, and 40-50 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with biotins using standard chemical labeling method. A standard biotin reagent (13.5 angstroms) is used in this product.

Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Less than 1.0 EU per μg by the LAL method.

>95% as determined by SDS-PAGE. 

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the COA.

For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 24 months in lyophilized state;
-70°C for 24 months under sterile conditions after reconstitution.

Please refer to product data sheet.

Clinical and Translational Updates

(1) "The heparin-binding domain of VEGF165 directly binds to integrin αvβ3 and plays a critical role in signaling"
Takada, Yu, Ye et al
bioRxiv (2023)
(2) "Complementary Gene Therapy after Revascularization with the Saphenous Vein in Diabetic Foot Syndrome"
Kupczyńska, Lubieniecki, Antkiewicz et al
Genes (Basel) (2023) 14 (10)
(3) "Inducing Angiogenesis in the Nucleus Pulposus"
Damle, Krzyzanowska, Korsun et al
Cells (2023) 12 (20)
Showing 1-3 of 1907 papers.